OSAKA-BUSINESS-DEV-AGCY
15.12.2022 06:01:35 CET | Business Wire | Press release
The Osaka Business Development Agency, in cooperation with the Keihanshin Startup Ecosystem Consortium and JETRO Osaka, has jointly launched the brand, “Kansai Startup Mashups” to support startups from the Kansai region that are taking on global challenges. From this release and on, we will use "Kansai Startup Mashups" as a branding tool to promote various initiatives for startups in the Kansai region to the global market.
The first event will be held on January 25, 2023, and the call for participants begins today.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221214005391/en/
Kansai Startup Mashups in Kobe, 25 / Jan / 2023. (Graphic: Business Wire)
Osaka, Kyoto, and Kobe offer an environment conducive to startups, with a concentration of bio- and healthcare-related companies, Monozukuri (manufacturing), ICT-related companies, as well as universities and research institutes.
Due to its strength environment, the "Osaka-Kyoto-Kobe(Hyogo) Consortium" was selected in 2020 as a global hub city in the Japanese government's strategy to become a world-class start-up hub, and universities, companies, and local governments are working to form an ecosystem of collaboration.
And now, with the aim to further accelerate these efforts, Osaka, Kyoto, and Kobe have jointly launched "Kansai Startup Mashups" as a unified brand for support.
The newly launched "Kansai Startup Mashups" aims to create a world-class startup ecosystem in anticipation of the 2025 Kansai Expo and the post-Kansai Expo, and to create a framework that will lead to the birth of unicorn companies from the Kansai region and the creation and support of startups that will grow to become major players.
In this initiative, the three capitals of Osaka, Kyoto, and Kobe will collaborate to link the circle of cooperation and support among universities, businesses, and government, and to disseminate Kansai startups both domestically and internationally, creating new synergies through the exchange of cutting-edge technology and domestic and international wisdom.
As part of this effort, toward the end of the fiscal year, we will be holding three events under a unified brand; ANCHOR KOBE on Wednesday, January 25, 2023 and engawa KYOTO on February 7, 2023.
On March 2, 2023, a large-scale event will be held at QUINTBRIDGE (Osaka) to unify and communicate the potential of Kyoto, Osaka, and Kobe to become the world's first to realize a future society on the occasion of the Osaka-Kansai Expo.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221214005391/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom